(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.
The Cambridge, England-based pharmaceutical company said Ultomiris and Soliris "can transform" patient outcomes in sufferers of rare neurological diseases.
Astra will present data from its rare neurology portfolio at the American Academy of Neurology meeting in Denver, Colorado next week.
The data will add to the "robust evidence supporting the safety and efficacy" of Ultomiris and Soliris in sufferers of myasthenia gravis and neuromyelitis optica spectrum disorder, the company said. Myasthenia gravis causes muscle weakness, while NMOSD affects optic nerves and the spinal cord.
Presentations will include new long-term results from phase 3 Champion-NMOSD trials, alongside real-world data.
Astra shares were 0.6% lower at 10,556.00 pence each on Monday morning in London.
Astra and partner Daiichi Sankyo Co Ltd on Saturday said the US Food & Drug Administration has approved their cancer drug conjugate Enhertu for patients with metastatic HER2-positive solid tumours.
By Tom Budszus, Alliance News slot editor
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Astrazeneca (AZN)
